Komori
Mochida Pharmaceutical (4534) · InitiativeRestated

Business Continuity and Supply Maintenance Measures in Response to COVID-19

First written in FY2020. 1 of 3 entries say "Advanced", first in FY2021. Latest entry: FY2022.

3entries
3years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2020AdvancedFY20212020: 120202021: 120212022: 12022
Same theme, other companies
Maintaining Product Supply and Business Continuity During COVID-19A theme 180 companies write about · 50 as a headwind · 127 as a tailwind

The whole theme swung hardest in 2026: 1 of 12 companies on the "Worse" side.

108 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 180 companies compared. The sentences above are computed from all 180.
Full recordFilings, disclosures and news, newest first
  1. FY2022RestatedAnnual report

    「The Company has established a COVID-19 task force headed by the President and is determining policies covering both infection prevention and business continuity across the Group. For employees, the Company recommends working from home and staggered working hours and is taking thorough measures to prevent infections.」

    The company continues its business continuity measures, including the task force, working from home and staggered working hours, stable supply, and digital marketing.
  2. FY2021AdvancedAnnual report

    「The Company has established a COVID-19 task force headed by the President and is determining policies covering both infection prevention and business continuity across the Group. For employees, the Company recommends working from home and staggered working hours and is taking thorough measures to prevent infections. Medical representative (MR) activities involve providing information while actively using digital marketing, with the conditions at each medical institution assessed individually.」

    In addition to operating the task force, the company discloses specific measures for infection prevention and business continuity, including working from home, staggered working hours, and MR activities using digital marketing.
  3. FY2020First statedAnnual report

    「Regarding the ongoing COVID-19 pandemic, the Company has established a task force headed by the President and is determining and implementing policies covering both infection prevention and business continuity across the Group.」

    In response to COVID-19, the company discloses for the first time as a standalone initiative the establishment of a task force headed by the President and efforts to prevent infections and maintain business continuity.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Mochida Pharmaceutical yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Business Continuity and Supply Maintenance Measures in Response to COVID-19 | Mochida Pharmaceutical Co.,Ltd. (4534) | Komori